AstraZeneca holds talks with Bristol Myers Squibb on $400B megadeal: report

Nypost · Aug 02, 2026 · 250 words · By Reuters

headphones Listen to the eFinder podcast briefing

Generate a natural audio summary of this story

Daily briefing

What to know about AstraZeneca holds talks with Bristol Myers Squibb on $400B megadeal: report

AstraZeneca holds talks with Bristol Myers Squibb on $400B megadeal: report See more of our coverage in your search results.

Claims checked 7

Techniques found 0

Topics 0

Coverage spectrum

Coverage gap: Low Left coverage

Left0%

Center67%

Right33%

3 sources compared across this story cluster. This is an eFinder estimate from indexed source coverage, not an editorial rating.

What happened

AstraZeneca holds talks with Bristol Myers Squibb on $400B megadeal: report See more of our coverage in your search results.

Why it matters

Add The New York Post on Google UK drugmaker AstraZeneca has been exploring a deal to combine with US rival Bristol Myers Squibb, the Financial Times reported on Sunday, citing people familiar with the matter.

Common ground

The deal could create one of the world’s biggest pharmaceutical groups with a combined value of nearly $400 billion.

Perspective signals

No major persuasion pattern has been attached yet, so the source, headline, and evidence should carry most of the weight for readers.

Follow-up questions

What concrete event or decision sits underneath the headline: AstraZeneca holds talks with Bristol Myers Squibb on $400B megadeal: report?
What evidence would most clearly confirm or weaken the claim that Cancer treatments accounted for about $25 billion in 2025 sales?
What happens next if the deal stalls, and who has the power to restart talks?

open_in_new Read the original article: https://nypost.com/2026/08/02/business/astrazeneca-holds-talks-with-bristol-myer…

fact_checkClaims Checked

eFinder analyzed this article and checked 7 claims against available evidence, cross-references, web search, and Wikipedia. Here is what the fact-checking layer found.

check_circle Corroborated 7

check_circle

Claim 1: “Cancer treatments accounted for about $25 billion in 2025 sales”

CORROBORATED

The $25 billion figure for cancer treatment sales in 2025 is consistently reported by CNBC, The Enterprise World, and other news sources.

menu_book

wikipedia NEUTRAL — AstraZeneca () (AZ) is a Swedish–British multinational pharmaceutical and biotechnology company with its headquarters at the Cambridge Biomedical Campus in Cambridge, England. It has a portfolio of pr…
https://en.wikipedia.org/wiki/AstraZeneca

menu_book

wikipedia NEUTRAL — The Oxford–AstraZeneca COVID‑19 vaccine, sold under the brand names Covishield and Vaxzevria among others, is a viral vector vaccine for the prevention of COVID-19. It was developed in the United King…
https://en.wikipedia.org/wiki/Oxford–AstraZeneca_COVID-19_va…

menu_book

wikipedia NEUTRAL — Sir Pascal Claude Roland Soriot (born 23 May 1959) is a French-born Australian businessman and chief executive of the British-Swedish multinational pharmaceutical and biotechnology company AstraZeneca…
https://en.wikipedia.org/wiki/Pascal_Soriot

+ 4 more evidence sources

check_circle

Claim 2: “cardiovascular, renal and metabolism treatments worth about $12 billion”

CORROBORATED

The $12 billion figure for cardiovascular, renal, and metabolism treatments is corroborated by CNBC, The Global Economics, and The Enterprise World.

menu_book

wikipedia NEUTRAL — Quetiapine ( kwi-TY-ə-peen), sold under the brand name Seroquel among others, is an atypical antipsychotic medication used in the treatment of schizophrenia, bipolar disorder, and major depressive dis…
https://en.wikipedia.org/wiki/Quetiapine

+ 4 more evidence sources

check_circle

Claim 3: “The report of the potential deal comes about a dozen years after AstraZeneca fended off a takeover attempt by larger US rival Pfizer.”

CORROBORATED

Multiple sources, including BBC News and other reports, confirm that AstraZeneca rejected a takeover bid from Pfizer in 2014 (approximately 11-12 years ago).

travel_explore

web search NEUTRAL — Why is AstraZeneca — which rejected Pfizer's $118 billion bid in 2014 — now pursuing this? In 2014, Soriot argued AstraZeneca could generate greater long-term value as an independent company rebuildin…
https://www.techtimes.com/articles/322735/20260802/astrazene…

travel_explore

web search NEUTRAL — The board of AstraZeneca has rejected the improved $119 billion takeover offer from U.S. drugmaker Pfizer.
https://www.nbcnews.com/business/business-news/astrazeneca-r…

travel_explore

web search NEUTRAL — AstraZeneca chairman explains latest Pfizer bid rejection. UK drugs company AstraZeneca has rejected an improved "final" takeover offer from US drugs giant Pfizer. Pfizer had made a new offer of £55 p…
https://www.bbc.co.uk/news/business-27466278

check_circle

Claim 4: “UK drugmaker AstraZeneca has been exploring a deal to combine with US rival Bristol Myers Squibb, the Financial Times reported on Sunday”

CORROBORATED

Multiple independent sources, including the Financial Times (cited in LinkedIn, OncoDaily, and Editor's Corner) and Reuters, report that AstraZeneca and Bristol Myers Squibb have explored a merger.

menu_book

wikipedia NEUTRAL — Bristol-Myers Squibb Company, doing business as Bristol Myers Squibb, is an American multinational pharmaceutical company headquartered in Princeton, New Jersey. The company's primary products are api…
https://en.wikipedia.org/wiki/Bristol_Myers_Squibb

menu_book

wikipedia NEUTRAL — Samsung Biologics Co., Ltd. (Korean: 삼성바이오로직스) is a global contract development and manufacturing organization headquartered in Songdo, Incheon, South Korea. The biotech division of Samsung Group, its…
https://en.wikipedia.org/wiki/Samsung_Biologics

+ 3 more evidence sources

check_circle

Claim 5: “Last year, AstraZeneca unveiled plans for a direct US listing”

CORROBORATED

The claim that AstraZeneca unveiled plans for a direct US listing last year is reported by multiple web sources, including a report discussing the BMS merger talks.

travel_explore

web search NEUTRAL — [12] AstraZeneca traces its earliest corporate history to 1913, when Astra AB was formed by a large group of doctors and apothecaries in Södertälje. Throughout the twentieth century, it grew into the …
https://en.wikipedia.org/wiki/AstraZeneca

travel_explore

web search NEUTRAL — AstraZeneca is a global, science-led biopharmaceutical business and our innovative medicines are used by millions of patients worldwide.
https://www.astrazeneca.com/

travel_explore

web search NEUTRAL — Progress in oncology is measured by the lives we improve and extend. At AstraZeneca, we see how every breakthrough can change what is possible for patients and their families. That belief is driving u…
https://www.astrazeneca-us.com/

check_circle

Claim 6: “The deal could create one of the world’s biggest pharmaceutical groups with a combined value of nearly $400 billion.”

CORROBORATED

The combined value of nearly $400 billion is explicitly mentioned across multiple sources including Reuters, LinkedIn, and Editor's Corner.

menu_book

wikipedia NEUTRAL — The following is a list of independent pharmaceutical, biotechnology and medical companies listed on a stock exchange (as indicated) that have generated a revenue of at least US$10 billion, ranked by …
https://en.wikipedia.org/wiki/List_of_largest_biomedical_com…

menu_book

+ 3 more evidence sources

check_circle

Claim 7: “The company’s share price has more than quadrupled during Pascal Soriot’s 14-year tenure as CEO”

CORROBORATED

The fact that the share price more than quadrupled during Pascal Soriot's 14-year tenure is corroborated by CNBC and multiple web search results.

menu_book

+ 4 more evidence sources

info Disclaimer: This analysis is generated by AI and should be used as a starting point for critical thinking, not as definitive truth. Claims are verified against publicly available sources. Always consult the original article and additional sources for complete context.